PST-611

Phase 1Biologic

EEyevensys

PST-611 is one of 42 biologic programs targeting Dry Age Related Macular Degeneration. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Age-Related Macular DegenerationActive, not recruiting

Completed

Age-Related Macular DegenerationPhase 1

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Eylea

Regeneron

Phase 3

44 2

Lucentis

Roche

Phase 3

64 3

Vabysmo

Roche

Phase 3

13 4

Beovu

Novartis

Phase 3

10 5

Macugen

Pfizer

Phase 3

6 6

Avastin

BBio-Thera Solutions

Phase 3

18 7

Retaane

AAlcon Research

Phase 3

5 8

Forzinity

SStealth BioTherapeutics Inc.

Phase 3

2 9

Kenalog

BBausch Health Americas, Inc.

Phase 3

2 10

Aquasol E

NNational Eye Institute (NEI)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dry Age Related Macular Degeneration1 trial

An Open-label Single Ascending Dose Safety and Tolerability Clinical Trial of PST-611 in Subjects With Dry Age-related Macular Degeneration

Completed·EEyevensys·Phase 1·NCT07024732·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PST-611. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PST-611 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PST-611. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eyevensys company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: EEyevensys

PST-611

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dry Age Related Macular Degeneration1 trial

References

Drug Info

Quick Facts

Related News